HighTower Advisors
HUMA icon

HighTower Advisors’s Humacyte HUMA Stock Holding History

HighTower Advisors’s Portfolio HUMA Stock Details HUMA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$17.4K Sell
22,342
-743
-3% -$689 ﹤0.01% 3774
2026
Q1 		$14K Buy
23,085
+4,782
+26% +$4.97K ﹤0.01% 3774
2025
Q4 		$17.6K Sell
18,303
-500
-3% -$708 ﹤0.01% 3617
2025
Q3 		$32.7K Buy
18,803
+5,550
+42% +$10.9K ﹤0.01% 3644
2025
Q2 		$27.7K Buy
13,253
+2,500
+23% +$4.8K ﹤0.01% 3592
2025
Q1 		$18.3K Sell
10,753
-2,352
-18% -$8.83K ﹤0.01% 3524
2024
Q4 		$66.2K Buy
+13,105
New +$64.8K ﹤0.01% 3426

Other funds holding HUMA

AP
Antipodes Partners Royal Exchange, Australia $5.46B AUM 26.64% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $38.9B AUM 28.51% 1-Year Est. Return
DKCM
Davidson Kempner Capital Management New York $8.42B AUM 61.81% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $529M AUM 337.4% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

HighTower Advisors's HUMA Position: Q2 2026 in Review

HighTower Advisors reduced its Humacyte (HUMA) stake by 3.2% in Q2 2026, selling an estimated $689 and leaving 22,342 shares worth $17.4K. The position accounts for ﹤0.01% of the portfolio, ranked #3774.

HighTower Advisors first reported a position in HUMA in Q4 2024 and has held it in 7 quarters since. The position peaked at $66.2K in Q4 2024. 161 funds tracked by Wall St. Rank hold HUMA as of Q2 2026.

  • HighTower Advisors held 22,342 shares of Humacyte worth $17.4K as of Q2 2026.
  • HighTower Advisors sold 743 Humacyte shares in Q2 2026, an estimated $689.
  • Humacyte made up ﹤0.01% of HighTower Advisors's portfolio in Q2 2026, its #3774 holding.
  • HighTower Advisors first reported a position in Humacyte in Q4 2024 and has held it in 7 quarters since.
  • HighTower Advisors's Humacyte position peaked at $66.2K in Q4 2024.
  • 161 funds tracked by Wall St. Rank held Humacyte as of Q2 2026.

Based on HighTower Advisors's 13F filing for Q2 2026, filed 5 Aug 2026.